We are thrilled to announce our investment alongside Molten Ventures in IMU Biosciences as part of their £11.5M ($15M) Series A round. With IMU's profiling technology and AI platform, they are pioneering the development of the world's largest IMMUNE DATA ASSETS, unlocking the potential of precision medicine. Over the past 18 months, we have closely seen their tech and commercial progress, and we couldn't be more impressed. Congratulations to Adam Laing, Tom Hayday, Mario Cantero, Tim Haines, and the rest of the team. cc Amol Sarva Inaki Berenguer Rika Christanto Yue Z.
We are delighted to announce the completion of our £11.5 million Series A financing round, which was led by European Tech VC Molten Ventures, alongside LifeX Ventures and other investors. IMU Biosciences is focused on coupling deep, systems-level immune profiling with our proprietary AI platform, CytAtlas™, to build a uniquely detailed immune atlas that can fuel a new understanding of the immune system that was previously impossible. Our platform has the potential to power the future of translational research and clinical practice, from diagnostics to drug development and treatment response. The new capital raised will supercharge our next steps, including advancing our novel CytAtlas™ platform, fostering new strategic partnerships and projects, conducting cutting-edge, large-scale immune research, and expanding our operations into the US. You can read the full press release here: https://lnkd.in/dKNwjFSB #techbio #biotech #investment #immunooncology #immunology #precisionmedicine
IMU Biosciences is hiring for Data Platform Engineers in UK, Spain and Sweden. Take a look! ⛵️Per (Pelle) Ullberg, CTO IMU Biosciences